502482-44-2 Usage
Purpose
Used in the synthesis of pharmaceutical drugs and as a reagent in organic chemistry.
Classification
Piperazine derivative.
Protecting group
BOC (tert-butyloxycarbonyl) group at the 1-N position.
Substituent
Benzyl group at the 4-N position.
Building block
Acts as a building block in the synthesis of various medical drugs.
Pharmaceutical intermediates
Used to prepare various types of pharmaceutical intermediates.
Versatility
Utilized in research laboratories for organic synthesis due to its versatile chemical properties.
Reactivity
Ability to react with a variety of other compounds.
Check Digit Verification of cas no
The CAS Registry Mumber 502482-44-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 5,0,2,4,8 and 2 respectively; the second part has 2 digits, 4 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 502482-44:
(8*5)+(7*0)+(6*2)+(5*4)+(4*8)+(3*2)+(2*4)+(1*4)=122
122 % 10 = 2
So 502482-44-2 is a valid CAS Registry Number.
InChI:InChI=1/C18H28N2O2/c1-5-16-14-19(13-15-9-7-6-8-10-15)11-12-20(16)17(21)22-18(2,3)4/h6-10,16H,5,11-14H2,1-4H3/t16-/m0/s1
502482-44-2Relevant articles and documents
Novel Compounds
-
Page/Page column 20, (2008/12/04)
The invention relates to substituted aryl acids as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation.
PIPERAZINE UREA DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS
-
Page 81, (2010/11/30)
Certain novel piperazine urea derivatives are agonists of the human melanocortin-4 receptor (MC-4R) and, in particular, are receptor-subtype selective agonists of MC-4R. They are useful for the treatment, control, or prevention of diseases and disorders r
2-Substituted piperazines as constrained amino acids. Application to the synthesis of potent, non carboxylic acid inhibitors of farnesyltransferase [1]
Williams,Ciccarone,MacTough,Bock,Conner,Davide,Hamilton,Koblan,Kohl,Kral,Mosser,Omer,Pompliano,Rands,Schaber,Shah,Wilson,Gibbs,Graham,et al.
, p. 1345 - 1348 (2007/10/03)
-